PF-Atlas › Clinical Trials › NCT04531865

Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment

Rituximab · Phase 3

Registry ID
NCT04531865
Phase
Phase 3
Status
Withdrawn
Drug / intervention
Rituximab
Sponsor
Children's Hospital of Fudan University
Start
2021-01-01
Locations
4

About this trial

The aim of this study is to evaluate the efficacy and safety of maintenance Mycophenolate Mofetil following single course of Rituximab in maintaining remission over 12 months among Children with frequently-relapsing or steroid-dependent nephrotic syndrome

View NCT04531865 on ClinicalTrials.gov →

Explore related

All Rituximab trialsAll IPF trials

Related trials

Rituximab — NCT01086540Rituximab — NCT01862926Rituximab — NCT02990286Rituximab — NCT05596786Rituximab — NCT03069248Rituximab — NCT01969409
Medical disclaimer. This page summarizes public trial data for NCT04531865 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.